Rexulti vs Caplyta
A side-by-side look at two mental health medications advertised on TV. Informational only — not medical advice.
| US Rexulti | US Caplyta | |
|---|---|---|
| Generic name | brexpiprazole | lumateperone |
| Drug class | Atypical Antipsychotic | Atypical Antipsychotic |
| Treats | Major depression (add-on), schizophrenia, agitation in dementia | Schizophrenia, bipolar depression |
| Category | Mental Health | Mental Health |
| Manufacturer | Otsuka/Lundbeck | Intra-Cellular Therapies |
| Year approved | 2015 | 2019 |
| FDA warning | Black box warning | Black box warning |
| Est. TV ad spend | $170M | $130M |
| Common side effects | Weight gain, Restlessness, Drowsiness, Movement disorders | Drowsiness, Dry mouth, Dizziness, Nausea |
Frequently asked questions
Is Rexulti or Caplyta better?
Neither is universally "better." Rexulti (brexpiprazole) and Caplyta (lumateperone) are both used for mental health, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Rexulti and Caplyta?
Rexulti is a Atypical Antipsychotic made by Otsuka/Lundbeck, while Caplyta is a Atypical Antipsychotic made by Intra-Cellular Therapies. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Rexulti has the larger estimated TV advertising budget of the two.